Rodman & Renshaw Lowers Alto Neuroscience (NYSE:ANRO) to Neutral

Rodman & Renshaw lowered shares of Alto Neuroscience (NYSE:ANRO) from a buy rating to a neutral rating in a research report released on Wednesday, Marketbeat reports.

Other equities analysts have also issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Alto Neuroscience in a research note on Tuesday, September 10th. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $24.40.

Alto Neuroscience Stock Performance

Shares of Alto Neuroscience stock opened at $4.37 on Wednesday. Alto Neuroscience has a 12-month low of $3.93 and a 12-month high of $24.00. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04. The stock has a 50 day moving average price of $12.02 and a two-hundred day moving average price of $12.36.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. As a group, equities analysts predict that Alto Neuroscience will post -2.63 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Large investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at $21,267,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience in the first quarter valued at about $9,788,000. Vanguard Group Inc. bought a new position in Alto Neuroscience during the first quarter worth about $8,233,000. Jennison Associates LLC acquired a new stake in Alto Neuroscience during the first quarter valued at approximately $7,039,000. Finally, Artal Group S.A. bought a new stake in shares of Alto Neuroscience in the 1st quarter valued at approximately $5,372,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.